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This paper reports data on the bone, speciﬁcally the tibia and
mandible, of nonobese diabetic mice with severe combined
immunodeﬁciency disease (NOD–SCID mice) treated with zole-
dronic acid (ZA) and prednisolone (PSL). The data described here
are related to the research article titled “Zoledronic acid basically
increases circulating soluble RANKL level in mice, and in
glucocorticoid-administrated mice, more increases lymphocytes
derived sRANKL by bacterial endotoxic stimuli” [1]. The present
data and the NOD–SCID mice experiments described contain
insights into the role of bone-remodeling factors induced by ZA
treatment.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
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xillofacial Surgery, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo,
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ata accessibility The data are supplied with this articleD2. Value of the data The methodology provided can be used to evaluate the relationship between the immune response
and ZA in bone metabolism.
 These data are valuable to researchers benchmarking bone morphological changes according to
different medications.
 This approach would be useful for researchers studying the pathophysiology of medication-related
osteonecrosis of the jaw.3. Data
These data provide supporting information related to a comparison of the bone analysis of NOD–
SCID mice and C57BL/6JJc1 mice and circulating bone-remodeling factors [1]. Bone analysis of NOD–
SCID mice revealed a greater reduction in osteoblastogenesis with ZA treatment than without
treatment. To determine whether ZA treatment affects the bone volume and structure of the NOD–
SCID mouse mandible, we used microfocus X-ray computed tomography (μCT) to assess the man-
dibular microarchitecture, speciﬁcally, the bone volume/tissue volume and trabecular thickness.4. Experimental design, materials and methods
4.1. Experimental protocol
Animal experiments were conducted by reference to the ARRIVE Guidelines for Reporting Animal
Research [2] and have been described in detail previously [1]. Male NOD.CB17-Prkdcscid/J, so-called
NOD–SCID, mice (Charles River Japan, Yokohama, Japan) were obtained at 8 weeks of age. Fig. 1 shows
a schematic of the animal experimental protocol. For glucocorticoid and bisphosphonate (BP)
administration, slow-release pellets (Innovative Research of America, Sarasota, FL) of placebo or PSL
3.5 mg/kg/day were implanted into the lateral side of the neck of the mice, according to manu-
facturer's protocol. BP as zoledronic acid (ZA) was provided by Novartis Pharma AG (Basel, Switzer-
land). We treated the NOD–SCID mice with once-weekly subcutaneous injections of 100 μg/kg ZA or
with phosphate-buffered saline (PBS) alone. PSL and placebo pellets implanted into the NOD–SCID
mice were released over 21 days, and the weekly injections continued throughout the 21-day release
period (Figs. 2–4).
Placebo
PSL
0
#
1 2 [week]3
#
4
#
sacrifice
Slow-release pellets for 21 days
PBS
ZA
PBS
ZA
NOD-SCID mice
LPS injection into oral cavity
Placebo + PBS
Placebo + ZA
PSL + PBS
PSL + ZA
Fig. 1. Schematic of the animal experimental protocol. PBS, phosphate-buffered saline; PSL, prednisolone; ZA, zoledronic acid;
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Placebo + PBS PSL + PBS PSL + ZAPlacebo + ZA
µCT
H&E
Fig. 2. Representative images of the proximal region of the tibia in NOD–SCID mice.
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Microfocus X-ray computed tomography (μCT) (ELE SCAN; Nittetsu Elex Co. Ltd., Tokyo, Japan),
following the manufacturer's protocol, was used to obtain cross-sectional views of the secondary
spongiosa in the distal tibiae metaphysis at about 0.28 mm distal to the growth plate, with energy
67.0 kV, current 100 μA, and slice thickness 13.09 μm (n¼4 animals per group). The mandible
underwent microarchitectural analysis with μCT. The scanning conditions of the mandible were a
voxel size of 10 μm with an X-ray tube voltage of 67 kV and intensity current of 101 μA. The micro-
architectural properties of the mandible specimens were evaluated within a conforming volume of
interest, which was deﬁned as the bone area between the ﬁrst molar and second molar.
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Fig. 4. μCT analysis of the mandible of NOD–SCID mice. BV/TV (%), bone volume/tissue volume; Tb.Th (μm), trabecular
thickness. *po0.05 Compared with placeboþPBS group. #po0.05 Compared with the PSLþPBS and PSLþZA groups. n¼3 For
each treatment group.
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Fig. 3. Bone histomorphometric analysis of the tibia in NOD–SCID mice. BV/TV, bone volume/tissue volume; Tb.Th, trabecular
thickness; Tb.N, trabecular number; OV/BV, osteoid volume/bone volume; OS/BS, osteoid surface/bone surface; Ob.S/BS, osteoblast
surface/bone surface; ES/BS, eroded surface/bone surface; Oc.S/BS, osteoclast surface/bone surface; MAR, mineral apposition rate; BFR/
BV, bone formation rate/bone volume. *po0.05 Compared with placeboþPBS group. n¼4 For each treatment group.
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The bony specimens were ﬁxed, left undecalciﬁed, and embedded in ethanol (70–80%), which was
25-times the volume of the sample, based on the method of a previous study [1]. For calcein labeling,
4 days and 1 day before the sacriﬁce of the NOD–SCID mice, four mice in each group were given an
intraperitoneal injection of calcein (16 mg/kg; Dojindo, Kumamoto, Japan) for double labeling. A
computer and digitizer tablet (Histometry RT Camera; System Supply Co., Ltd., Nagano, Japan) were
used for histomorphometric examination, which was conducted by the Niigata Bone Science Institute
(Niigata, Japan). Usage of nomenclature, symbols, and units followed the recommendations of the
Nomenclature Committee of the American Society for Bone and Mineral Research [3].
4.4. Statistical analysis
Each result is the mean7SEM of three replicate measurements. Data were compared using one-
way analysis of variance (ANOVA) or Student's t-test and the threshold for statistical signiﬁcance was
set at po0.05.Acknowledgments
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